The human genome encodes 538 protein kinases that transfer a γ-phosphate group from
ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with …

Target-based drug discovery is the dominant paradigm of drug discovery; however, a
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …

Inhibition of the B-cell receptor pathway, and specifically of Bruton tyrosine kinase (BTK), is a
leading therapeutic strategy in B-cell malignancies, including chronic lymphocytic leukemia …

Bruton's tyrosine kinase (BTK) is a non-receptor intracellular kinase that belongs to the TEC-
family tyrosine kinases together with bone marrow-expressed kinase (BMX), redundant …

Targeted drugs and precision medicine have transformed the landscape of cancer therapy
and significantly improved patient outcomes in many cases. However, as therapies are …

Bruton's tyrosine kinase (BTK) plays a key role in the B-cell receptor (BCR) signaling
pathway and confers anti-apoptotic and proliferative properties to malignant B-cells in …

Osimertinib, a 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI), is the first-line standard-of-care for EGFR-mutant non-small cell lung cancer …

Bruton's tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor
(BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell …

We previously found that ibrutinib has anticancer activity in EGFR-mutant non–small cell
lung cancer (NSCLC). One of our recent studies showed that auranofin, a gold complex that …

Prostate cancer is the most commonly diagnosed cancer in men with African American men
disproportionally suffering from the burden of this disease. Biomarkers that could …